|
1
|
Swerdlow SH, Campo E, Pileri SA, Harris
NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz
AD and Jaffe ES: The 2016 revision of the World Health Organization
classification of lymphoid neoplasms. Blood. 127:2375–2390. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang P, Lin J, Liu H, Shen H and Yang HL:
Primary bone mantle cell lymphomas with multiple vertebral
compression fractures: A case report. Oncol Lett. 13:1288–1292.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao XF, Young KH, Frank D, Goradia A,
Glotzbecker MP, Pan W, Kersun LS, Leahey A, Dormans JP and Choi JK:
Pediatric primary bone lymphoma-diffuse large B-cell lymphoma:
Morphologic and immunohistochemical characteristics of 10 cases. Am
J Clin Pathol. 127:47–54. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li GP, Chen WZ, Huang HF, Chen JD, Lin XL
and Fu Q: Role of CyclinD1/IgH detection by FISH in differential
diagnostic significance between mantle cell lymphoma and chronic
lymphocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi.
23:1314–1317. 2015.(In Chinese). PubMed/NCBI
|
|
5
|
Carbone PP, Kaplan HS, Musshoff K,
Smithers DW and Tubiana M: Report of the committee on Hodgkin's
disease staging classification. Cancer Res. 31:1860–1861.
1971.PubMed/NCBI
|
|
6
|
Vitolo U, Seymour JF, Martelli M,
Illerhaus G, Illidge T, Zucca E, Campo E and Ladetto M; ESMO
Guidelines Committee, : Extranodal diffuse large B-cell lymphoma
(DLBCL) and primary mediastinal B-cell lymphoma: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 27:v91–v102. 2016.PubMed/NCBI
|
|
7
|
Dreyling M, Campo E, Hermine O,
Kluin-Nelemans HC, Le Gouill S, Rule S, Shpilberg O, Walewski J and
Ladetto M; ESMO Guidelines Working Group, : Newly diagnosed and
relapsed mantle cell lymphoma: ESMO clinical practice guidelines
for diagnosis, treatment and follow-up. Ann Oncol. 25 Suppl
3:iii83–iii92. 2017. View Article : Google Scholar
|
|
8
|
Klener P, Fronkova E, Belada D, Forsterova
K, Pytlik R, Kalinova M, Simkovic M, Salek D, Mocikova H, Prochazka
V, et al: Alternating R-CHOP and R-cytarabine is a safe and
effective regimen for transplant-ineligible patients with a newly
diagnosed mantle cell lymphoma. Hematol Oncol. 36:110–115. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Delarue R, Haioun C, Ribrag V, Brice P,
Delmer A, Tilly H, Salles G, Van Hoof A, Casasnovas O, Brousse N,
et al: CHOP and DHAP plus rituximab followed by autologous stem
cell transplantation in mantle cell lymphoma: A phase 2 study from
the Groupe d'Etude des Lymphomes de l'Adulte. Blood. 121:48–53.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tseng YD, Stevenson PA, Cassaday RD, Cowan
A, Till BG, Shadman M, Graf SA, Ermoian R, Smith SD, Holmberg LA,
et al: Total body irradiation is safe and similarly effective to
chemotherapy-only conditioning in autologous stem cell
transplantation for mantle cell lymphoma patients. Biol Blood
Marrow Transplant. 24:282–287. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Le Gouill S, Thieblemont C, Oberic L,
Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag
V, Feugier P, et al: Rituximab after autologous stem-cell
transplantation in mantle-cell lymphoma. N Eng J Med.
377:1250–1260. 2017. View Article : Google Scholar
|
